Risk of subsequent self-harm, suicide attempts and suicide following a first hospital-treated self-harm episode among young people: a population-based cohort study - Summary - MDSpire
Advertisement
Risk of subsequent self-harm, suicide attempts and suicide following a first hospital-treated self-harm episode among young people: a population-based cohort study
To estimate risk for subsequent self-harm, suicide attempts and suicide following a first hospital-treated self-harm event in young people.
Approach:
Study Population: Included 77,647 individuals (57.0% female) aged 10–24 years who experienced their first hospital-treated self-harm episode between 1973–2019.
Risk Estimation: Estimated cumulative incidence and incidence rates for subsequent self-harm, suicide attempts, and suicide at 1 month, 3 months, and 1 year post-initial episode.
Key Findings:
Cumulative incidence within 1 year: 17.3% (95% CI 17.0 to 17.5) for self-harm, 8.3% (95% CI 8.1 to 8.5) for suicide attempts, and 0.3% (95% CI 0.2 to 0.3) for suicide.
Highest risks occurred in the first month: 8.4% (95% CI 8.2 to 8.6) for self-harm, 2.9% (95% CI 2.8 to 3.0) for suicide attempts, and 0.04% (95% CI 0.03 to 0.05) for suicide.
Interpretation:
The month following a self-harm episode shows an elevated risk of subsequent self-harm, suicide attempts, and suicide, with risk remaining high over the year.
Limitations:
Study does not account for all potential confounding factors influencing self-harm and suicide risk.
Data is based on hospital-treated episodes, which may not represent all self-harm occurrences.
Conclusion:
The findings indicate elevated risks for subsequent self-harm, suicide attempts, and suicide following an initial hospital-treated self-harm episode.
by Thuy-Dung Nguyen, Moa Karemyr, Ralf Kuja-Halkola, Brian M D’Onofrio, Zheng Chang, Isabell Brikell, Paul Lichtenstein, Henrik Larsson, Patrick Sullivan, Yi Lu, Johan Bjureberg
Interviews with hospital leaders and employed physicians highlighted financial pressures, perceived care-integration benefits, and unresolved operational tensions following acquisition.
Online interest in leucovorin, folate products, and acetaminophen-related autism concerns increased markedly in the 2 weeks following the White House announcement.
